EyePoint Pharmaceuticals, Inc. (EYPT) vs Inhibikase Therapeutics, Inc. (IKT)
A side-by-side comparison of EyePoint Pharmaceuticals, Inc. and Inhibikase Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EYPT
EyePoint Pharmaceuticals, Inc.
$3.13HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
IKT
Inhibikase Therapeutics, Inc.
$1.99HealthcareDelayed quote: Oct 6, 2026, 1:29 PM EDT
Total return — EYPT vs IKT
growth of $100 · dividends reinvested · last 6yEYPT -32.1% (-6.3%/yr)IKT -96.6% (-43.2%/yr)EYPT compounded faster over this window
Log scale — wide-divergence pair
EYPT IKT
EYPT vs IKT: by the numbers
- •IKT is the larger company ($262M vs $262M market cap).
- •Both run net losses; IKT's is the smaller (0.00% vs -10994.73% net margin).
Metrics side by side
Valuation
| Metric | EYPT | IKT |
|---|---|---|
| P/S ratio | 93.94 | N/A |
| P/B ratio | 1.57 | 1.71 |
Profitability
| Metric | EYPT | IKT |
|---|---|---|
| Gross margin | 93.41% | 0.00% |
| Operating margin | -775.98% | 0.00% |
| Net margin | -10994.73% | 0.00% |
| ROE | -184.27% | -39.55% |
| ROIC | -170.19% | -42.92% |
Growth (annualized)
| Metric | EYPT | IKT |
|---|---|---|
| Revenue CAGR (5Y) | -41.05% | N/A |
| Total return CAGR (5Y) | -21.68% | -29.10% |
Frequently asked
- How have EYPT and IKT total returns compared?
- Over the past 5 years, EYPT delivered -21.68% and IKT delivered -29.10% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.